Table of Contents
Market Overview
According to the DataM market research report, the Global Idiopathic Pulmonary Fibrosis Market size reached US$ 2,184.4 million in 2022 and is expected to witness lucrative growth by reaching up to US$ 4,614.3 million by 2030. The global idiopathic pulmonary fibrosis market is projected to exhibit a CAGR of 10.1% during the forecast period (2023-2030). The most important market trend is the rising demand for robust pipeline medications.
The global market for idiopathic pulmonary fibrosis is driven by factors such as the increasing clinical trials of IPF drugs, the rising aging population, the availability of approved therapies, the expanding pipeline and investigational drugs, rising awareness & early diagnosis, and advances in research techniques.
The global idiopathic pulmonary fibrosis market is segmented on the basis of treatment, end-user, and region. North America holds the 40.2% marketplace percentage for the idiopathic pulmonary fibrosis marketplace in 2022 because of the excessive sickness burden and availability of authorized therapies.
The major global players include Roche Holdings AG, Boehringer Ingelheim GmbH, Genentech Inc., FibroGen Inc., Galapagos NV, MEDICINOVA INC., Bristol Myers Squibb Company, Biogen Inc., AstraZeneca PLC, and Novartis International AG.
For more details on this report Request for Sample: www.datamintelligence.com/download-sample/idiopathic-pulmonary-fibrosis-market
Market Drivers:
The availability of approved therapies for the treatment of idiopathic pulmonary fibrosis is the major factor driving the market share during the forecast period. The approval of antifibrotic medications, such as pirfenidone and nintedanib, demonstrated efficacy in slowing disease progression and improving patient outcomes. The availability of approved therapies has not only provided treatment options but also increased the overall interest and investment in IPF research and development.
Market Restraints:
The side effects of the treatment and the limited treatment options associated with idiopathic pulmonary fibrosis are the major factors expected to hamper the market growth. Despite the availability of approved therapies, the treatment options for IPF are still limited. Antifibrotic drugs, such as pirfenidone and nintedanib, are the mainstay of treatment, but they are not curative and only slow disease progression, which can limit the treatment options for patients.
Market Opportunities:
Early and accurate diagnosis of IPF is crucial for initiating timely treatment and improving patient outcomes. Advancements in imaging techniques, such as high-resolution computed tomography (HRCT) and biomarker testing, can aid in the early detection and differentiation of IPF. Companies that develop improved diagnostic tools and techniques can capture a significant market share.
View Full Report: www.datamintelligence.com/research-report/idiopathic-pulmonary-fibrosis-market
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the idiopathic pulmonary fibrosis market. COVID-19 primarily affects the respiratory system, and individuals with pre-existing lung conditions, including IPF, are at a higher risk of developing severe illness if they contract the virus. The heightened vulnerability of IPF patients to COVID-19 has led to increased attention to their care, management, and protection.
The COVID-19 pandemic highlighted the importance of respiratory health and increased awareness about lung diseases, including IPF. This heightened focus on respiratory health may drive attention, research, and funding toward IPF and other pulmonary fibrosis conditions.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war significantly impacted the idiopathic pulmonary fibrosis market growth. The conflict may affect international collaborations and research initiatives involving Russian and Ukrainian healthcare institutions, pharmaceutical companies, and academic organizations.
Collaboration and exchange of scientific knowledge are crucial for advancing IPF research and developing new therapies. Political tensions and restrictions on collaboration can impede progress and hinder the exchange of expertise and resources, leading to a negative impact on the idiopathic pulmonary fibrosis market globally.
Recent Developments in the Industry
- In May 2023, Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for a Phase II study in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. As a result, Cumberland will launch its FIGHTING FIBROSIS trial designed to enroll 128 patients in over 20 medical centers of excellence across the U.S.
- In May 2023, Simulations Plus, Inc., a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced the release of a new integrated pulmonary software and services package. This targeted package will support pharmaceutical companies by streamlining their pulmonary drug development processes, enabling them to make better-informed decisions and bring therapies to market faster.
Market Segmentation
As per the research analysis, the global idiopathic pulmonary fibrosis market is segmented by treatment into drugs, oxygen therapy, pulmonary rehabilitation, lung transplant, and others; by end-user into hospitals, clinics, and others.
- Based on the treatment, the market for drugs segment holds 45.3% of the global idiopathic pulmonary fibrosis market share in 2022. The drugs segment includes pharmaceutical interventions for IPF, such as antifibrotic medications and potential future therapies.
Antifibrotic drugs, such as pirfenidone and nintedanib, have gained wide acceptance and are considered the standard of care for IPF. These medications have been extensively studied in clinical trials and have been shown to slow the decline in lung function and prolong survival. The high adoption of antifibrotic medications by healthcare professionals contributes to the dominance of the drugs segment.
Geographical Analysis
The global idiopathic pulmonary fibrosis market is segmented into North America, Europe, South America, Asia Pacific, and Middle East & Africa.
North America Idiopathic Pulmonary Fibrosis Market
North America holds the 40.2% market share for the idiopathic pulmonary fibrosis market in 2022 due to the high disease burden and availability of approved therapies. North America has a relatively high prevalence of IPF compared to other regions. The aging population, environmental factors, and genetic predisposition contribute to the increased disease burden in this region.
Competitive Landscape:
The major global players include Roche Holdings AG, Boehringer Ingelheim GmbH, Genentech Inc., FibroGen Inc., Galapagos NV, MEDICINOVA INC., Bristol Myers Squibb Company, Biogen Inc., AstraZeneca PLC, and Novartis International AG.
Suggestions for Related Report
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query with regard to the scope offered will be addressed within 24- 48 hours.
3) An Excel sheet with market numbers will be provided separately.
The Full Report has the below insights:
- The report offers a comprehensive evaluation of the market in terms of market value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2021-2022) and verifiable projections about market size during the forecast period (2023-2030).
- Visualize the composition of the global idiopathic pulmonary fibrosis market by treatment, end-user, and region, highlighting the key commercial assets and players.
- By Treatment: drugs, oxygen therapy, pulmonary rehabilitation, lung transplant, others
- By End-User: hospitals, clinics, others.
- By Region: North America, South America, Europe, Asia Pacific, Middle East & Africa
- Identify commercial opportunities in the global idiopathic pulmonary fibrosis market by analyzing trends and co-development deals.
- The report also covers data insights on various industry forces such as Porter’s five forces analysis, supply chain analysis, pricing analysis, regulatory analysis.
- Excel data sheet with thousands of data points of global idiopathic pulmonary fibrosis market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in Excel for the key product of all major market players
The report will provide access to approximately 61 market data tables, 64 figures and close to 180 pages.
About Us:
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you.
We encompass a multitude of Syndicate Reports & Customized Reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
